AU2020258002B2 - Novel MEK-inhibitor for the treatment of viral and bacterial infections - Google Patents

Novel MEK-inhibitor for the treatment of viral and bacterial infections

Info

Publication number
AU2020258002B2
AU2020258002B2 AU2020258002A AU2020258002A AU2020258002B2 AU 2020258002 B2 AU2020258002 B2 AU 2020258002B2 AU 2020258002 A AU2020258002 A AU 2020258002A AU 2020258002 A AU2020258002 A AU 2020258002A AU 2020258002 B2 AU2020258002 B2 AU 2020258002B2
Authority
AU
Australia
Prior art keywords
virus
aureus
infection
treatment
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020258002A
Other languages
English (en)
Other versions
AU2020258002A1 (en
Inventor
Oliver Planz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atriva Therapeutics GmbH
Original Assignee
Atriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics GmbH filed Critical Atriva Therapeutics GmbH
Publication of AU2020258002A1 publication Critical patent/AU2020258002A1/en
Application granted granted Critical
Publication of AU2020258002B2 publication Critical patent/AU2020258002B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020258002A 2019-04-16 2020-04-16 Novel MEK-inhibitor for the treatment of viral and bacterial infections Active AU2020258002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU101183 2019-04-16
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Publications (2)

Publication Number Publication Date
AU2020258002A1 AU2020258002A1 (en) 2021-11-18
AU2020258002B2 true AU2020258002B2 (en) 2025-12-18

Family

ID=66554457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020258002A Active AU2020258002B2 (en) 2019-04-16 2020-04-16 Novel MEK-inhibitor for the treatment of viral and bacterial infections

Country Status (13)

Country Link
US (1) US12350244B2 (https=)
EP (1) EP3955908B1 (https=)
JP (2) JP2022529343A (https=)
KR (1) KR20210153642A (https=)
CN (1) CN114007598A (https=)
AU (1) AU2020258002B2 (https=)
BR (1) BR112021020605A2 (https=)
CA (1) CA3136171A1 (https=)
EA (1) EA202192454A1 (https=)
ES (1) ES3012533T3 (https=)
LU (1) LU101183B1 (https=)
MX (1) MX2021012604A (https=)
WO (1) WO2020212478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
CN119931962B (zh) * 2025-04-07 2025-08-05 北京华诺泰生物医药科技有限公司 一种人偏肺病毒的培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
KR20020012315A (ko) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2014056894A1 (en) 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
CN113398271A (zh) 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) * 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTIN, B. et al., "Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound", Scientific Reports. 2018, vol. 8, pages 1-11. *
HAASBACH, E. et al., "The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo", Antiviral Research. 2017, vol 142, pages 178-184. *
MARTIN, L. "PD0184264, an active metabolite of the MEK-inhibitor CI-1040 shows superior pharmacokinetics and antiviral activity against influenza virus", 6th International Influenza Meeting, 08 Sep 2018. *

Also Published As

Publication number Publication date
JP2025124703A (ja) 2025-08-26
KR20210153642A (ko) 2021-12-17
EA202192454A1 (ru) 2022-03-22
JP2022529343A (ja) 2022-06-21
LU101183B1 (en) 2020-10-16
CA3136171A1 (en) 2020-10-22
CN114007598A (zh) 2022-02-01
US20220193017A1 (en) 2022-06-23
AU2020258002A1 (en) 2021-11-18
ES3012533T3 (en) 2025-04-09
BR112021020605A2 (pt) 2021-12-07
EP3955908A1 (en) 2022-02-23
MX2021012604A (es) 2021-11-12
US12350244B2 (en) 2025-07-08
WO2020212478A1 (en) 2020-10-22
EP3955908C0 (en) 2025-01-22
EP3955908B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
AU2024205853A1 (en) Novel MEK-inhibitor for the treatment of viral and bacterial infections
AU2020258002B2 (en) Novel MEK-inhibitor for the treatment of viral and bacterial infections
AU2020256326B2 (en) Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections
US20100113430A1 (en) Thioxanthene derivates useful to treat infectious diseases
US20140066451A1 (en) Thioxanthene derivatives for the treatment of infectious diseases
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)